房角镜辅助下内路360°小梁切开术治疗玻璃体切除术后继发性高眼压

Gonioscopy-assisted transluminal trabeculotomy for secondary high intraocular pressure after vitrectomy

摘要:

目的：探讨房角镜辅助下内路360°小梁切开术(GATT)治疗玻璃体切除术后继发性高眼压的临床疗效。方法：回顾性研究。纳入2019-01/2022-05在成都市第一人民医院眼科行GATT治疗的玻璃体切除术后继发性高眼压患者10例15眼。记录术前，术后1d，1wk，1、3、6mo最佳矫正视力(BCVA)、眼压、使用的降眼压药物数量及术中、术后并发症，并分析手术成功率。结果：术前和术后6mo时BCVA比较无差异(Z=0，P=1)。术后1d，1wk，1、3、6mo平均眼压17.47±3.78、18.8±3.29、19.13±3.62、20.31±3.66、18.03±3.23mmHg较术前(28.33±9.48mmHg)降低(均P<0.05)； 术后6mo平均用药 1(0，2)种 ，较术前[2(2，4)种]显著下降(P<0.001)； 术后 1d，1wk，1、3、6mo手术总成功率分别为87%(13眼)、93%(14眼)、87%(13眼)、73%(11眼)、93%(14眼)； 术后主要并发症为短暂性前房积血(10眼，67%)，一过性眼压升高(5眼，33%)，未发生其他严重影响视力的并发症。结论：GATT治疗玻璃体切除术后继发性高眼压安全有效。

Abstract:

AIM: To investigate the clinical efficacy of gonioscopy-assisted transluminal trabeculotomy(GATT)for secondary high intraocular pressure after vitrectomy.METHODS: A retrospective study was conducted on 10 patients(15 eyes)with secondary high intraocular pressure(IOP)after vitrectomy treated with GATT in Department of Ophthalmology, Chengdu First People's Hospital from January 2019 to May 2022. The best-corrected visual acuity(BCVA), IOP, number of IOP-lowering drugs, and complications before operation and at 1d, 1wk, 1, 3 and 6mo after operation were recorded, and the surgical success rate was analyzed.RESULTS:There was no difference in BCVA before and 6mo after operation(Z=0, P=1). The mean IOP decreased from 28.33±9.48mmHg to 17.47±3.78(1d), 18.8±3.29(1wk), 19.13±3.62(1mo), 20.31±3.66(3mo)and 18.03±3.23mmHg(6mo; all P<0.05). The average medication used before surgery was 2(2, 4), and the average medication used 6mo after surgery was 1(0, 2), which was significantly decreased(P<0.001). The total success rate of surgery at 1d, 1wk, 1, 3 and 6mo after surgery was 87%(13 eyes), 93%(14 eyes), 87%(13 eyes), 73%(11 eyes)and 93%(14 eyes)respectively. The main postoperative complications were transient hyphema(10 eyes, 67%)and transient elevated IOP(5 eyes, 33%). No complications seriously affecting the vision occurred.CONCLUSION: GATT is safe and effective in the treatment of secondary high intraocular pressure after vitrectomy.